Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00034915.xml
Download PDF
Onkologische Welt 2017; 08(06): 278-281
DOI: 10.1055/s-0038-1639655
DOI: 10.1055/s-0038-1639655
DGHO 2017 Stuttgart
Fortschritte bei der Therapie – ein Update
Akute lymphatische LeukämieAuthors
Further Information
Publication History
Publication Date:
10 March 2018 (online)
Die akute lymphatische Leukämie (ALL) ist die häufigste bösartige Erkrankung im Kindesalter. Auf dem DGHO-Kongress beschäftigte sich ein Symposium mit den aktuellen Therapiekonzepten – von der Chemotherapie bis zur CART-Zelle.
-
Literatur
- 1 Möricke A. et al. Dexamethason vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood 2016; 127 (17) 2101-2112.
- 2 Dagdan E. et al. The strong prognostic effect of concurrent deletions of IKZF1 and PAX5, CDKN2A, CDKN2B or PAR1 in the Absence of ERG deletions (IKZF1plus) in pediatric Acute Lymphoblastic Leukemia strongly depends on minimal residual disease burden after induction treatment. Blood 2014; 124: 131.
- 3 Iacobucci I, Mullighan CG. Genetic Basis of Acute Lymphoblastic Leukemia. JCO 2017; 35 (09) 975-983.
- 4 Roberts KG. et al. Targetable kinase-activating lesions in Ph-like Acute Lymphoblastic Leukemia. NEJM 2014; 371: 1005-1015.
- 5 Santiago R. et al. Novel therapy for childhood acute lymphoblastic leukemia. Expert Opin Pharmacother 2017; 18 (11) 1081-1099.
- 6 Hagemeijer A, Graux C. ABL1 rearrangements in T-cell acute lymphoblastic leukemia. Genes Chromosomes Cancer 2010; 49 (04) 299-308.
- 7 Katarjian HM. et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. NEJM 2017; 376 (09) 836-847.
- 8 Katarjian HM. et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. NEJM 2016; 375 (08) 740-753.
- 9 Gökbuget N. et al. BLAST: A Confirmatory, Single-Arm, Phase 2 Study of Blinatumomab, a Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Patients with Minimal Residual Disease B-Precursor Acute Lymphoblastic Leukemia (ALL). Blood. 2014
- 10 Buechner J. et al. Global registration trial of efficacy and safety of CTL019 in pediatric and young adult patients with relapsed/refractory (r/r) ALL: Update to the Interim Analysis. EHA 2017, Abstract S476.
- 11 Hay KA. et al. Kinetics and Biomarkers of Severe Cytokine Release Syndrome after CD19 Chimeric Antigen Receptor-modified T Cell Therapy. Blood. 2017 Vorabpublikation, doi: 10.1182/blood-2017–06–793141.